Shots:

• The P-III ARAMIS trial involves assessing of Darolutamide (600 mg- bid) + androgen deprivation therapy (ADT) vs PBO + ADT in 1509 patients in the ratio (2:1) with nmCRPC
• P-III ARAMIS study results: mMFS (40.4 vs 18.4 mos.); 59% reduction in risk of metastasis or death; time to pain progression (40.3 vs 25.4 mos.); PFS (36.8 vs 14.8 mos.); 62% risk reduction of local progression- Presented at ASCO GU in San Francisco
• Darolutamide is an androgen receptor antagonist inhibiting the receptor function and the growth of prostate cancer cells and is evaluated in P-III ARASENS for metastatic hormone-sensitive prostate cancer

Ref: Bayer | Image: The Business Journals